
AI News
Insilico Medicine Advances AI-Designed Drug to Phase III Trials
Insilico Medicine is pushing its AI-discovered drug, rentosertib, into Phase III clinical trials for idiopathic pulmonary fibrosis. The move marks a significant shift for the computational drug discovery sector, transitioning from theoretical promise to late-stage efficacy validation for a treatment identified and engineered entirely through proprietary algorithmic pipelines.




.jpg)




















